VETIGENICS ANNOUNCES SECOND DISCOVERY COLLABORATION WITH A MAJOR ANIMAL HEALTH PHARMA
Tue, November 8, 2022, 10:00 AM
Vetigenics, an animal health biotechnology company, today announced a second discovery collaboration with a major animal health pharmaceutical company for use of the VETIGENICS CANIBODY™ Platform. The aim is to jointly discover and develop novel therapeutic antibodies to treat chronic diseases of companion animals. read more
Vetigenics is an animal health biopharmaceutical company committed to improving canine health through the development of entirely canine, safe and effective antibody-based immunotherapies to treat cancer, infectious disease and other chronic conditions. The company’s founders, Nicola Mason, BVetMed, PhD and Don Siegel MD, PhD of the University of Pennsylvania are internationally recognized leaders in veterinary medicine, immunotherapy, and phage display technology. Their complementary expertise naturally resulted in an unrivalled ability to generate and validate entirely canine antibodies therapeutics.
Vetigenics seeks strategic collaborations to further utilize the depth and breadth of its proprietary phage display libraries such as target discovery and development partnerships.Read More